SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55: 236442.
  • 2
    Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 2000;9: 8087.
  • 3
    Grant R, Shorvon SD. Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy. Epilepsy Res 2000;42: 8995.
  • 4
    Shorvon SD, Lowenthal A, Janz D, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures: European, Levetiracetam Study, Group. Epilepsia 2000;41: 11791186.
  • 5
    Kumar SP, Smith PE. Levetiracetam as add-on therapy in generalised epilepsies. Seizure 2004;13: 475477.
  • 6
    Greenhill L, Betts T, Smith K. Effect of levetiracetam on resistant juvenile myoclonic epilepsy [Abstract]. Epilepsia 2001;42(suppl 7):179.
  • 7
    Krauss GL, Betts T, Abou-Khalil B, et al. Levetiracetam treatment of idiopathic generalised epilepsy. Seizure 2003;12: 617620.
  • 8
    Genton P, Gelisse P. Antimyoclonic effect of levetiracetam. Epileptic Disord 2000;2: 209212.
  • 9
    Frucht SJ, Louis ED, Chuang C, et al. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology 2001;57: 11121114.
  • 10
    Kasteleijn-Nolst Trenite DG, Marescaux C, Stodieck S, et al. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs: evaluation of the piracetam analogue, levetiracetam. Epilepsy Res 1996;25: 225230.
  • 11
    Bourgeois BFD, Holder DL, Valencia I, et al. Open-label assessment of levetiracetam efficacy and adverse effects in a pediatric population [Abstract]. Epilepsia 2001;42(suppl 7):5354.
  • 12
    Tan MJ, Appleton RE. Efficacy and tolerability of levetiracetam in children aged 10 years and younger: a clinical experience. Seizure 2004;13: 142145.
  • 13
    Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy: European, Levetiracetam Study, Group. Epilepsia 2000;41: 12761283.
  • 14
    Alsaadi TM, Koopmans S, Apperson M, et al. Levetiracetam monotherapy for elderly patients with epilepsy. Seizure 2004;13: 5860.
  • 15
    Alsaadi TM, Thieman C, Zusman EE. Levetiracetam monotherapy for adults with localization-related epilepsy. Epilepsy Behav 2002;3: 471474.
  • 16
    Alsaadi TM, Thieman C. Levetiracetam monotherapy for newly diagnosed epilepsy patients. Seizure 2003;12: 154156.
  • 17
    Madeja M, Margineanu DG, Gorji A, et al. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? Neuropharmacology 2003;45: 661671.
  • 18
    Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002;43: 918.
  • 19
    Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices. Neurosci, Lett 2001;306: 58.
  • 20
    Pisani A, Bonsi P, Martella G, et al. Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine. Epilepsia 2004;45: 719728.
  • 21
    Zona C, Niespodziany I, Marchetti C, et al. Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type, Ca2+ currents. Seizure 2001;10: 279286.
  • 22
    Rigo JM, Hans G, Nguyen L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 2002;136: 659672.
  • 23
    Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc, Natl Acad, Sci U S A 2004;101: 98619866.
  • 24
    Löscher W, Honack D, Rundfeldt C. Antiepileptic effects of the novel anticonvulsant levetiracetam (ucb LO59) in the kndling model of temporal epilepsy. J Pharmacol Exp Ther 1998;285: 474479.
  • 25
    Löscher W, Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 1988;2: 145181.
  • 26
    Gower AJ, Hirsch E, Boehrer A, et al. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res 1995;22: 207213.
  • 27
    Gower AJ, Noyer M, Verloes R, et al. Ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur J Pharmacol 1992;222: 193203. Erratum published in: Eur J Pharmacol 1993;230:389.
  • 28
    Klitgaard H, Matagne A, Gobert J, et al. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 1998;353: 191206.
  • 29
    Löscher W, Hönack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol 1993;232: 147158.
  • 30
    Patsalos PN. Levetiracetam: pharmacology and therapeutics in the treatment of epilepsy and other neurological conditions. Rev Contemp Pharmacother 2004;13: 1168.
  • 31
    Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure 2000;9: 464468.
  • 32
    Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342: 314319.
  • 33
    Perucca E. Pharmacological principles as a basis for polytherapy. Acta Neurol Scand Suppl 1995;162: 3134.
  • 34
    Genton P, Roger J. Antiepileptic drug monotherapy versus polytherapy: a historical prospective. Epilepsia 1997;38(suppl 5):S2S5.
  • 35
    Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003;2: 347356.
  • 36
    Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003;2: 473481.
  • 37
    Patsalos PN, Fröscher W, Pisani F, et al. The importance of drug interactions in epilepsy therapy. Epilepsia 2002;43: 365385.
  • 38
    Deckers CLP, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000;41: 13641374.
  • 39
    Stephen LJ, Brodie MJ. Seizure-freedom with more than one antiepileptic drug. Seizure 2002;11: 349351.
  • 40
    Luszczki JJ, Ratnaraj N, Patsalos PN, et al. Pharmacodynamic and pharmacokinetic interaction studies of loreclezole and felbamate, lamotrigine, topiramate and oxcarbazepine in the mouse maximal electroshock seizure model. Epilepsia 2005;46: 344355.
  • 41
    Sills GJ, Butler E, Thompson GG, et al. Pharmacodynamic interaction studies with topiramate in the pentylenetetrazol and maximal electroshock seizure models. Seizure 2004;13: 287295.
  • 42
    Mazarati AM, Baldwin R, Klitgaard H, et al. Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticus. Epilepsy Res 2004;58: 167174.
  • 43
    Sisodiya SM, Sander JW, Patsalos PN. Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy Res 2002;48: 217219.
  • 44
    Glauser TA, Pellock JM, Bebin EM, et al. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia 2002;43: 518524.
  • 45
    Luszczki JJ, Borowicz KK, Swiader M, et al. Interactions between oxcarbazepine and conventional antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 2003;44: 489499.
  • 46
    Luszczki JJ, Czuczwar M, Kis J, et al. Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 2003;44: 10031013.
  • 47
    Luszczki JJ, Czuczwar SJ. Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis. Epilepsia 2004;45: 895907.
  • 48
    Luszczki JJ, Czuczwar SJ. Isobolographic and subthreshold methods in the detection of interactions between oxcarbazepine and conventional antiepileptics: a comparative study. Epilepsy Res 2003;56: 2742.
  • 49
    Litchfield JT, Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 1949;96: 99113.
  • 50
    Luszczki J, Swiader M, Czuczwar M, et al. Interactions of tiagabine with some antiepileptics in the maximal electroshock in mice. Pharmacol Biochem Behav 2003;75: 319327.
  • 51
    Porreca F, Jiang Q, Tallarida RJ. Modulation of morphine antinociception by peripheral [Leu5]enkephalin: a synergistic interaction. Eur J Pharmacol 1990;179: 463468
  • 52
    Borowicz KK, Swiader M, Luszczki J, et al. Effect of gabapentin on the anticonvulsant activity of antiepileptic drugs against electroconvulsions in mice: an isobolographic analysis. Epilepsia 2002;43: 956963.
  • 53
    Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 1953;3: 285290.
  • 54
    Berenbaum MC. What is synergy? Pharmacol Rev 1989;41: 93141.
  • 55
    Tallarida RJ. Drug Synergism and Dose-effect Data Analysis. Boca Raton : Chapman & Hall/CRC, 2000.
  • 56
    Bourgeois BFD, Wad N. Combined administration of carbamazepine and phenobarbital: effect on anticonvulsant activity and neurotoxicity. Epilepsia 1988;29: 482487.
  • 57
    Luszczki JJ, Czuczwar SJ. Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study. Naunyn Schmiedebergs Arch Pharmacol 2004;369: 434446.
  • 58
    Ratnaraj N, Doheny HC, Patsalos PN. A micromethod for the determination of the new antiepileptic drug levetiracetam (UCB LO59) in serum or plasma by high performance liquid chromatography. Ther Drug Monit 1996;18: 157164.
  • 59
    Boissier JR, Tardy J, Diverres JC. Une nouvelle méthode simple pour explorer l'action tranquilisante: le test de la cheminée. Med Exp (Basel) 1960;3: 8184.
  • 60
    Venault P, Chapouthier G, de Carvalho LP, et al. Benzodiazepines impair and beta-carbolines enhance performance in learning and memory tasks. Nature 1986;321: 864866
  • 61
    Luszczki JJ, Swiader M, Parada-Turska J, et al. Tiagabine synergistically interacts with gabapentin in the electroconvulsive threshold test in mice. Neuropsychopharmacology 2003;28: 18171830.
  • 62
    Luszczki JJ, Wojcik-Cwikla J, Andres MM, et al. Pharmacological and behavioral characteristics of interactions between vigabatrin and conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic analysis. Neuropsychopharmacology 2005;30: 958973.
  • 63
    Shank RP, Gardocki IF, Streeter AJ, et al. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanisms of action. Epilepsia 2000;41(suppl 1):S3S9.
  • 64
    Gibbs JW 3rd, Sombati S, DeLorenzo RJ, et al. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 2000;41(suppl 1):S10S16.
  • 65
    Skradski S, White HS. Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia 2000;41(suppl 1):S45S47.
  • 66
    Zhang X, Velumian AA, Jones OT, et al. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia 2000;41(suppl 1):S52S60.
  • 67
    Luszczki JJ, Andres MM, Czuczwar P, et al. Levetiracetam selectively psychopotentiates the acute neurotoxic effects of topiramate and carbamazepine in the rotarod test in mice. Eur Neuropharmacol 2005;15: 609616.
  • 68
    Schmidt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav 2004;5: 627635.
  • 69
    Kelly K, Stephen LJ, Brodie MJ. Levetiracetam for people with mental retardation and refractory epilepsy. Epilepsy Behav 2004;5: 878883.
  • 70
    Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000;85: 7785.
  • 71
    Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004;43: 707724.
  • 72
    Perucca E, Gidal BE, Baltes E. Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. Epilepsy Res 2003;53: 4756.
  • 73
    May TW, Rambeck B, Jurgens U. Serum concentrations of levetiracetam in epileptic patients: the influence of dose and co-medication. Ther Drug Monit 2003;25: 690699.